Targeted PARP1 inhibition has proven especially effective as a treatment for patients carrying a BRCA1 mutation, and in triple-negative breast cancer (because of the similarities with BRCA1-mutated tumors) leading to an inhibition of dual DNA repair pathways leading to cell death [42]. The gene discussed is BRCA1; the disease is triple-negative breast carcinoma.